fda compounding semaglutide news november 2025 Novo Nordisk expands legal action to protect US patients from unsafe, non- FDA-approved compounded "semaglutide" Beyond the Headlines: FDA Warning

A (Yael Horwitz): Many users (40% in our member survey) take compounded GLP-1s, which often dont appear in claims data, which makes it harder for employers and plans to track ROI or manage spend effectively

Attend expert-led Workshops (in person or virtual) and connect with others on similar journeys

Worsening metabolic disease from regain increases healthcare utilization, medication costs for diabetes and cardiovascular conditions, and potential surgical interventions

While the evidence is not yet definitive, some researchers suggest that long-term exposure to GLP-1 drugs could potentially influence the activity of the guts L-cells the cells responsible for producing natural GLP-1 and related hormones such as GLP-2, which helps maintain the integrity of the intestinal lining